| IPO Company Profile © ipodata.com |
| Message Board | Quote | Chart | News | SEC Filings | Peer IPO Companies |
| ACLARA BioSciences, Inc. |
| 1288 Pear Avenue, Mountain View, CA 94043 * (650) 210-1200 |
| Business Description | The company believes that it is the only microfluidics, or lab-on-a-chip, company with access to the wide range of technology and intellectual property required to broadly address the genomics and pharmaceutical drug screening markets. |
| Offering Information Company has | |||
| Trading As | ACLA (NASNTL) | Industry | Manufacturing (SIC 3826) |
| Type of Stock Offered | Common Shares | Filing Date | 1/20/00 |
| Domestic Shares Offered | 9,000,000 | Offer Date | 3/20/00 |
| Foreign Shares Offered | 0 | Filing Range | $16.00 - $18.00 |
| Company Shares | 9,000,000 | Offer Price | $21.00 |
| Selling Shrhldrs Shares | 0 | Gross Spread | $1.470 |
| Gross Proceeds | $189,000,000 | Selling | $0.880 |
| Expenses | - - | Reallowance | $0.100 |
| Post-IPO Shares | 31,100,000 | Employees | - - |
| Primary Underwriting Group | ||
| Underwriter Name | Participation | Underwriter Phone |
| Deutsch Banc Alex. Brown | Lead Manager | (410) 727-1700 |
| U.S. Bancorp Piper Jaffray | Co-manager | (612) 342-6220 |
| Warburg Dillon Read LLC | Co-manager | (203) 719-3000 |
| Income Statement and Cash Flow Summary | |||||||
| Prior Audited Income |
Latest Unaudited Income | ||||||
| Full Year Audited Figures | 9 Months Ending | ||||||
| Figures in U.S. millions except per share data | 12/31/95 | 12/31/96 | 12/31/97 | 12/31/98 | 9/30/98 | 9/30/99 | |
| Revenues | - | 0.193 | 1.324 | 2.649 | 1.353 | 0.882 | 2.080 |
| Income from Oper. | - | -0.486 | -0.978 | -2.000 | -5.392 | -4.023 | -5.114 |
| Net Income | - | -0.455 | -0.956 | -1.998 | -5.522 | -4.069 | -4.930 |
| E.P.S | - | - | - | - | - | - | - |
| Revenue Growth (%) | - | 586.01 | 100.08 | -48.924 | 135.83 | ||
| Net Income Growth (%) | - | - | - | - | - | ||
| Oper. Profit Margin (%) | - | - | - | - | - | - | - |
| Net Profit Margin (%) | - | - | - | - | - | - | - |
| Cash Flow - Oper. | -4.84 | -3.84 | -3.53 | ||||
| Cash Flow - Inv. | -0.04 | 0.01 | -7.70 | ||||
| Cash Flow - Fin. | 6.39 | 6.44 | 17.35 | ||||
| Balance Sheet Summary and Financial Ratios | |||||
| Balance sheet as of: 9/30/99 | Financial Ratios | ||||
| Total Assets | 17.27 | Current Assets | 11.64 | Current Ratio | 5.19 |
| Total Liab. | 35.93 | Current Liab. | 2.24 | Debt Ratio | 207.99% |
| Total Equity | -18.65 | Working Cap. | 9.40 | Debt to Equity Ratio | - |
| Cash | 7.86 | Return on Assets | - | ||
| Use Of Proceeds |
The proceeds from the proposed offering will be used for research and development activities, for process development, for financing possible acquisitions and investments in technology as well as for working capital and other general corporate purposes. |
| Legal Counsel Registrar Auditor | |
| Issuer's Law Firm | Latham & Watkins |
| Bank's Law Firm | Wilson, Sonsini, Goodrich & Rosati |
| Registrar/Transfer Agent | ChaseMellon Shareholder Services, L.L.C. |
| Auditor | Pricewaterhouse Coopers LLC |
| Send us feedback if you would like to request that we hyperlink a firm on this page | |
| Principal Shareholders | ||
| Name of Shareholder | % Owned Before | % Owned After |
| Entities affiliated with Ampersand Ventures | 19.50 | |
| PE Corporation | 11.30 | |
| Entities affiliated with Alta Partners | 10.00 | |
| Johnson & Johnson Development Corporation | 9.80 | |
| Entities affiliated with CMEA Ventures | 8.20 | |
| Burrill & Company | 7.50 | |
| Asea Brown Boveri, Inc. | 5.60 | |
| Note: represents ownership of 5% or more prior to the offering. | ||